- Previous Close
10.50 - Open
10.40 - Bid 10.26 x --
- Ask 10.35 x --
- Day's Range
10.17 - 10.60 - 52 Week Range
6.34 - 40.90 - Volume
569,110 - Avg. Volume
716,317 - Market Cap (intraday)
476.739M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.43 - Earnings Date Feb 11, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 4, 2019
- 1y Target Est
9.50
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
www.mobergpharma.se10
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MOB.ST
View MorePerformance Overview: MOB.ST
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOB.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOB.ST
View MoreValuation Measures
Market Cap
476.74M
Enterprise Value
171.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
46.03
Price/Book (mrq)
0.51
Enterprise Value/Revenue
19.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-207.75%
Return on Assets (ttm)
-2.00%
Return on Equity (ttm)
-2.36%
Revenue (ttm)
8.78M
Net Income Avi to Common (ttm)
-18.25M
Diluted EPS (ttm)
-0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
308.96M
Total Debt/Equity (mrq)
0.40%
Levered Free Cash Flow (ttm)
-120.82M